Baker United Pharmaceutical Company currently has more than 700 employees, and R&D personnel account for 20% of the total number. At present, the company's total assets are 600 million yuan, with a total area of 308 mu (205,333 square meters), and it has a complete industrial chain from raw material research and development to preparation production and sales. At the same time, Baker and Pharmaceutical Co., Ltd. undertakes the construction and research projects of Anhui Chiral Pharmaceutical Engineering Technology Research Center, providing strong support for enterprise development.
Baker United Pharmaceutical Co., Ltd. has mastered the international leading core technology of chiral drugs, and has the largest domestic production capacity and the most comprehensive production base of anti-HBV and anti-AIDS raw materials, which has pioneered the localization of anti-HBV and anti-AIDS drugs and ended China's long-term dependence on imported antiviral drugs.
Baker United Pharmaceutical Co., Ltd. has clearly stated in the Twelfth Five-Year Plan that during the Twelfth Five-Year Plan period, according to the requirements of the national strategic emerging industry development plan, the enterprise will be built into a research and development and production base for anti-AIDS and hepatitis B treatment and biopharmaceuticals in China, benefiting patients in China and the world and contributing to human health; The second phase of the company's API base construction was fully launched on 20 12 (including two international new molecular drug projects: multi-target drugs for diabetes and multi-target drugs for cardiovascular diseases); All self-produced APIs have been submitted for production and put into the market; The company is promoting the listing process of small and medium-sized board; By the end of the "Twelfth Five-Year Plan", the company can achieve an annual output value of more than 654.38+0 billion yuan, profits and taxes of 654.38+0.5 billion yuan, and export earnings of 600 million US dollars.
The company will develop products with scientific and technological innovation, stabilize production with management innovation, open up markets with service innovation, and actively pass the international registration certification such as on-site certification of FDA in the United States to achieve international market access and vigorously explore the international market.
Grasping the historical opportunity of development, adhering to the enterprise purpose and adhering to the enterprise mission, Baker United Pharmaceutical will finally realize the vision of "keeping hepatitis B and AIDS away from human beings".
Anhui Baker United Pharmaceutical Co., Ltd. has the international leading synthetic technology of chiral compounds, and is one of the leading enterprises in China to develop and produce high-quality anti-AIDS drugs, APIs and their intermediates. The company integrates scientific research, development and production, and takes scientific and technological innovation and providing high-quality drugs for mankind as its consistent purpose. The company covers a total area of 205 128 square meters (308 mu), of which the raw material drug production base covers an area of10/0556 square meters (166 mu); The preparation factory covers an area of 77,256 square meters (1 16 mu); R&D Center covers an area of17,316 square meters (26 mu).
The company has a strong R&D team and an independent R&D center, including five doctors and 12 masters, and carries out R&D work under the guidance of researchers and senior engineers who enjoy the subsidies from the State Council. The company not only has a perfect quality assurance system, but also adheres to the concept of environmental protection for many years, establishes an advanced sewage and waste gas treatment device, and completes the recovery and treatment of various wastewater and waste gas with high standards and high requirements, and all emission indicators meet the national requirements. Lamivudine API was approved by Health Canada;
Establish active partnerships with many multinational pharmaceutical companies; Lafutidine API has obtained the GMP certificate issued by the US Food and Drug Administration, and the certificate number is Wan J 0253.
Lamivudine API has obtained the GMP certificate issued by the US Food and Drug Administration, and the certificate number is Anhui K 0276.
Anhui Baker Biopharmaceutical Co., Ltd. successfully passed GMP certification;
British QVT Fund LP Investment Fund invested US$ 65,438+0,000,000;
Slillan capsule has passed GMP certification, put into the market, and registered investment in the world. In June, 2007, British QVT Company invested1000000 USD to establish Anhui Baker United Pharmaceutical Co., Ltd. with Anhui Baker Pharmaceutical Co., Ltd. ... The company continued to innovate and develop the technology and scale of its antiviral and anti-AIDS drugs.
In September 2007, the company invested 65.438+0.6 billion yuan (about 23 million US dollars) to build a new API production base in Taihe Industrial Park, which was officially put into production that year. In April 2008, Anhui Baker United Pharmaceutical Co., Ltd. invested 6.5438+30.7 million yuan (about 6.5438+0.9 million US dollars) to wholly acquire a biopharmaceutical company located in Hefei High-tech Industrial Development Zone, and established Anhui Baker Biopharmaceutical Co., Ltd. to develop and produce first-and second-line pharmaceutical preparations for treating hepatitis B and AIDS.
From June, 5438 to February, 2008, Anhui Baker Pharmaceutical Management Co., Ltd. was approved to be established, and passed the on-site acceptance of the provincial US Food and Drug Administration in March, 2009. The total assets of Anhui Baker United Pharmaceutical Co., Ltd. are 5 1 billion RMB (about 75 million US dollars).